1. SCNX reported $590K net revenue growth, up from $65K last year. 2. Gross profit surged to $575K from just $4K in Q3 2024. 3. First FDA-approved product, Arbli™, launched successfully. 4. Access extended to over 100 million covered lives. 5. Upcoming launch of REZENOPY™, a life-saving opioid treatment, in Q1 2026.
The significant revenue and profit increases, along with market penetration and upcoming product launches, suggest robust future growth potential for SCNX. Historical performance indicates that successful product launches often lead to stock price surges, exemplified by similar biotech stocks post-FDA approvals.
The article highlights transformative financial growth and strategic product launches that are likely to impact SCNX's market perceptions positively. The figures presented indicate solid operational improvements and strategic advancements.
The potential revenue streams from Arbli and REZENOPY launch could enhance SCNX's financial health over the next several quarters, contributing to sustained stock price appreciation. Long-term growth will depend on continued product adoption and market expansion.
Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K
Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension
COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Highlights Compared to Third Quarter 2024:
"Q3 was a transformational quarter for Scienture as we commenced sales of Arbli™," commented Narasimhan Mani, President and Co-CEO of Scienture. "We delivered strong results this quarter, with significant increases in net revenues and gross profit as we entered full commercial scale-up of our first FDA-approved product, Arbli™. In the past month, Arbli™ was added to key national payor formularies, expanding access to over 100 million covered lives, and we secured GPO agreements reaching more than 2,500 healthcare institutions, representing potential penetration into roughly 20% of the U.S. institutional market. As we broaden our marketing efforts and demand builds across retail, institutional, and long-term care channels, we see significant potential for sustained adoption and long-term value creation. Subsequent to the end of the third quarter, we fundamentally strengthened our balance sheet by substantially reducing our outstanding debt and significantly enhancing our cash position to over $8 million as of November 13, 2025. Having optimized our capital structure, we are now strongly positioned and adequately capitalized to advance our commercial and operational priorities."
"Backed by a strong commercial infrastructure and the successful launch of Arbli™, Scienture is preparing to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment, in Q1 2026," stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. "REZENOPY® is the most potent naloxone HCl product currently available, leveraging a proven active ingredient and delivery method while offering increased effectiveness against today's more powerful opioids. Additionally, our development pipeline remains strong, and we continue to evaluate additional opportunities to add accretive products to our commercial portfolio. Delivering sustained shareholder value remains the Company's core priority."
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: "SCNX"), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, our strategies related to those products, and our future financial condition and results from operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
(Tables follow)
Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed Consolidated Balance Sheets
As of September 30, 2025 and December 31, 2024
(Unaudited)
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 355,692 | $ | 308,096 | ||||
| Accounts receivable, net | 590,050 | 11,106 | ||||||
| Inventory | 234,521 | - | ||||||
| Prepaid expenses | 240,811 | 4,560 | ||||||
| Notes receivable - related party | - | 1,300,000 | ||||||
| Other receivables | - | 4,138,770 | ||||||
| Deferred offering costs | - | 534,800 | ||||||
| Current assets of discontinued operations | - | 8,145 | ||||||
| Total current assets | 1,421,074 | 6,305,477 | ||||||
| Property, plant and equipment, net | 16,000 | 17,500 | ||||||
| Deposits | - | 22,039 | ||||||
| Notes receivable | 5,000,000 | - | ||||||
| Interest receivable | 62,500 | - | ||||||
| Intangible assets, net | 76,400,000 | 76,400,000 | ||||||
| Goodwill | 21,372,960 | 21,372,960 | ||||||
| Operating lease right-of-use assets | 23,360 | 201,433 | ||||||
| Deferred tax asset | 534,396 | 534,396 | ||||||
| Total assets | $ | 104,830,290 | $ | 104,853,805 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,672,860 | $ | 2,898,683 | ||||
| Accrued liabilities | 984,825 | 1,313,731 | ||||||
| Other current liabilities | - | 5,441 | ||||||
| Loan payable, related party | 531,000 | 415,000 | ||||||
| Convertible note, net of debt discount - current portion | 2,000,000 | 2,285,423 | ||||||
| Operating lease liability - current | 24,137 | 63,334 | ||||||
| Warrant liability | 138,624 | 919,935 | ||||||
| Current liabilities of discontinued operations | - | 5,346 | ||||||
| Total current liabilities | 7,351,446 | 7,906,893 | ||||||
| Convertible notes, net of debt discount | - | 612,275 | ||||||
| Derivative liability | - | 2,296,834 | ||||||
| Operating lease liability - net of current portion | - | 156,469 | ||||||
| Development agreement liability | 1,285,000 | 1,285,000 | ||||||
| Deferred tax liability | 13,524,213 | 13,524,213 | ||||||
| Total liabilities | 22,160,659 | 25,781,684 | ||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders' equity (deficit): | ||||||||
| Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 | - | - | ||||||
| Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 | - | - | ||||||
| Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 | - | - | ||||||
| Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both September 30, 2025 and December 31, 2024 | - | - | ||||||
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 23,132,260 and 8,750,582 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 231 | 87 | ||||||
| Additional paid-in capital | 135,100,304 | 118,111,007 | ||||||
| Accumulated deficit | (52,430,904 | ) | (39,038,973 | ) | ||||
| Total stockholders' equity | 82,669,631 | 79,072,121 | ||||||
| Total liabilities and stockholders' equity | $ | 104,830,290 | $ | 104,853,805 | ||||
Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.
Condensed Consolidated Statements Of Operations
For the Three and Nine Months Ended September 30, 2025 and 2024
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | $ | 590,050 | $ | 64,861 | $ | 600,308 | $ | 83,560 | ||||||||
| Cost of goods sold | 15,429 | 60,978 | 25,014 | 80,380 | ||||||||||||
| Gross profit | 574,621 | 3,883 | 575,294 | 3,180 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Wage and salary expense | 251,747 | 708,977 | 1,721,554 | 1,243,621 | ||||||||||||
| Professional fees | 1,320,845 | 593,364 | 1,943,458 | 1,282,053 | ||||||||||||
| Accounting and legal expense | 1,018,737 | 619,227 | 1,871,245 | 1,129,982 | ||||||||||||
| Technology expense | 9,756 | 157,474 | 92,784 | 295,763 | ||||||||||||
| General and administrative | 2,165,398 | 168,649 | 6,449,110 | 5,284,231 | ||||||||||||
| Research and development | 169,344 | 1,253,983 | 1,587,572 | 1,253,983 | ||||||||||||
| Total operating expenses | 4,935,827 | 3,501,674 | 13,665,723 | 10,489,633 | ||||||||||||
| Operating loss | (4,361,206 | ) | (3,497,791 | ) | (13,090,429 | ) | (10,486,453 | ) | ||||||||
| Non-operating income (expense): | ||||||||||||||||
| Change in fair value of warrant liability | 59,203 | 502,178 | 781,311 | (392,843 | ) | |||||||||||
| Change in fair value of derivative liability | 2,356,428 | - | 2,296,834 | - | ||||||||||||
| Loss on conversion of note payable | 43,200 | - | (53,446 | ) | - | |||||||||||
| Loss on disposition of subsidiaries | 97,324 | - | (288,204 | ) | - | |||||||||||
| Interest income | 1,120 | 29,445 | 89,710 | 133,397 | ||||||||||||
| Loss on disposal of asset | - | - | - | (374,968 | ) | |||||||||||
| Interest expense | (1,803,430 | ) | (217,433 | ) | (3,127,707 | ) | (320,897 | ) | ||||||||
| Total non-operating expense | 753,845 | 314,190 | (301,502 | ) | (955,311 | ) | ||||||||||
| Net loss from continuing operations | (3,607,361 | ) | (3,183,601 | ) | (13,391,931 | ) | (11,441,764 | ) | ||||||||
| Benefit / (provision) for income taxes | - | - | - | - | ||||||||||||
| Net loss from continuing operations, net of tax | (3,607,361 | ) | (3,183,601 | ) | (13,391,931 | ) | (11,441,764 | ) | ||||||||
| Net income from discontinued operations, net of tax | - | - | - | 27,670,294 | ||||||||||||
| Net (loss) income | $ | (3,607,361 | ) | $ | (3,183,601 | ) | $ | (13,391,931 | ) | $ | 16,228,530 | |||||
| Net loss per common share from continuing operations | ||||||||||||||||
| Basic | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | (7.10 | ) | ||||
| Diluted | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | (7.10 | ) | ||||
| Net (loss) income per common share from discontinued operations | ||||||||||||||||
| Basic | $ | - | $ | - | $ | - | $ | 17.17 | ||||||||
| Diluted | $ | - | $ | - | $ | - | $ | 14.64 | ||||||||
| Net (loss) income per common share | ||||||||||||||||
| Basic | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | 10.07 | |||||
| Diluted | $ | (0.19 | ) | $ | (1.34 | ) | $ | (0.94 | ) | $ | 8.59 | |||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 18,957,653 | 2,373,848 | 14,269,905 | 1,611,221 | ||||||||||||
| Diluted | 18,957,653 | 2,373,848 | 14,269,905 | 1,889,504 | ||||||||||||
